Zeaxanthin
Based on 2 publication(s) in Google Scholar
Zeaxanthin, a diet-obtained carotenoid, presents in the macula region of the eye. Zeaxanthin shows antioxidant effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.0%
- CAS No.: 144-68-3
- Formule: C40H56O2
- Masse moléculaire:568.87
-
Stockage:
-20°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Zeaxanthin
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Apoptosis Analysis
-
WB
-
Histological Imaging/Staining
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Microbial Metabolite |
Human Endogenous Metabolite |
Much of the Lutein and Zeaxanthin in the leaves of plants is protein-bound.In fruits and flower petals, the xanthophylls are esterified and are concentrated into chromoplasts where they are found to be solubilized in the membranes. In humans and higher animals, Lutein and Zeaxanthin are accumulated in lipophilic tissues such as adipose tissue and are carried in the blood by the lipoproteins, probably in a nonspecific manner similar to cholesterol. Lutein and Zeaxanthin are distributed equally between LDL and HDL fractions in human blood, in contrast to the hydrocarbon carotenoids that are preferentially found in LDL fractions, up to 75%[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 144-68-3
-
Appearance Solid
-
Masse moléculaire 568.87
-
Formule C40H56O2
-
Color Brown to reddish brown
-
SMILES
CC1(C)C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C[C@@H](O)CC2(C)C)=C(C)C[C@@H](O)C1
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Transl Oncol
Zeaxanthin targets TOP2A to regulate autophagy and suppress lung cancer progression via the MAPK/ERK pathway. [Abstract]2026 Feb:64:102658. PMID: 41496415
Zeaxanthin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2026 Feb:64:102658. [Abstract]
Cell viability assessed by CCK-8 assay treated with Zeaxanthin (Zea) (98.17 μM).
Zeaxanthin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2026 Feb:64:102658. [Abstract]
Cell migration detected by Transwell treated with Zeaxanthin (Zea) (98.17 μM).
Zeaxanthin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2026 Feb:64:102658. [Abstract]
Cell apoptosis measured by flow cytometry treated with Zeaxanthin (Zea) (98.17 μM).
Zeaxanthin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2026 Feb:64:102658. [Abstract]
WB analysis of MAPK/ERK pathway proteins. A549 cells: NC, Zeaxanthin (Zea) (98.17 μM).
Zeaxanthin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2026 Feb:64:102658. [Abstract]
HE staining images of mouse tumor tissues treated with Zeaxanthin (Zea) (50 mg/kg, i.g.).
-
Exp Eye Res
2025 Oct:259:110557. PMID: 40738388
Solvant et solubilité
THF : ≥ 10 mg/mL (17.58 mM)
DMSO : 1 mg/mL (1.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Bone RA, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997 Feb;64(2):211-8. [Content Brief]
[2]. Elbaz-Hayoun S, et al. Evaluation of antioxidant treatments for the modulation of macrophage function in the context of retinal degeneration. Mol Vis. 2019 Sep 5;25:479-488. [Content Brief]
[3]. Krinsky NI, et al. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye.Annu Rev Nutr. 2003;23:171-201. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / THF | 1 mM | 1.7579 mL | 8.7894 mL | 17.5787 mL | 43.9468 mL |
| THF | 5 mM | 0.3516 mL | 1.7579 mL | 3.5157 mL | 8.7894 mL |
| 10 mM | 0.1758 mL | 0.8789 mL | 1.7579 mL | 4.3947 mL | |
| 15 mM | 0.1172 mL | 0.5860 mL | 1.1719 mL | 2.9298 mL |
Zeaxanthin Related Classifications
HY-120318 Related Classifications
Powered by Bioz